CA
INO icon

CoreCap Advisors’s Inovio Pharmaceuticals INO Stock Holding History

CoreCap Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18 Hold
16
– – ﹤0.01% 3147
2026
Q1 		$28 Hold
16
– – ﹤0.01% 2900
2025
Q4 		$28 Hold
16
– – ﹤0.01% 2922
2025
Q3 		$37 Hold
16
– – ﹤0.01% 2764
2025
Q2 		$33 Sell
16
-1,340
-99% -$2.57K ﹤0.01% 2721
2025
Q1 		$2.21K Buy
1,356
+1,340
+8,375% +$2.69K ﹤0.01% 2321
2024
Q4 		$29 Hold
16
– – ﹤0.01% 2812
2024
Q3 		$92 Sell
16
-41
-72% -$338 ﹤0.01% 2559
2024
Q2 		$461 Buy
57
+41
+256% +$431 ﹤0.01% 1458
2024
Q1 		$222 Buy
+16
New +$138 ﹤0.01% 2402
2022
Q4 		$312 Buy
+17
New +$385 ﹤0.01% 2229
2022
Q3 		– Sell
-17
Closed – – 1272
2022
Q2 		$0 Buy
+17
New +$479 ﹤0.01% 2200
2022
Q1 		– Sell
-17
Closed -$1K – 1274
2021
Q4 		$1K Buy
+17
New +$1.36K ﹤0.01% 2150

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CoreCap Advisors's INO Position: Q2 2026 in Review

CoreCap Advisors held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 16 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #3147.

CoreCap Advisors first reported a position in INO in Q4 2021 and has held it in 13 quarters since. The position peaked at $2.21K in Q1 2025. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • CoreCap Advisors held 16 shares of Inovio Pharmaceuticals worth $18 as of Q2 2026.
  • CoreCap Advisors left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #3147 holding.
  • CoreCap Advisors first reported a position in Inovio Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • CoreCap Advisors's Inovio Pharmaceuticals position peaked at $2.21K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.